Nachrichten zur Novartis AG Aktie

Why Novartis (NVS) is a Top Dividend Stock for Your Portfolio

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy…

2 Dividend Stocks Defying the Tariff-Fueled Market Correction to Buy and Hold Forever

Equities are down this year because of Donald Trumps trade policies. The 47th U.S. president decided to impose steep tariffs…

Novartis (NVS) Unleashes $23BN Strategic Investment Masterstroke

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S. investment.…

Novartis (NVS) Surges 4.0%: Is This an Indication of Further Gains?

Novartis (NVS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate…

The Zacks Analyst Blog AbbVies, Rinvoq and AstraZenecas and Novartis

AbbVies, Rinvoq and AstraZenecas and Novartis are included in this Analyst Blog.…

Novartis investing $23B on US manufacturing, R&D buildup

Novartis plans to spend $23 billion over the next five years to expand its manufacturing, research and technology presence in…

NVS Plans to Invest $23B in US Manufacturing Sites Amid Tariff Threat

Novartis plans to expand its current manufacturing, research and technology presence in the United States following Trumps announcement of tariffs…

Pharmalittle: Were reading about FDA drug reviews, Novartis investing $23 billion in the U.S., and more

While FDA drug and device reviewers and inspectors were protected from layoffs, drug reviews are likely to be affected, anyway…

Pharma: Novartis will 23 Milliarden Dollar in den USA investieren

Das Schweizer Unternehmen will alle wichtigen Medikamente für den US-Markt künftig vor Ort produzieren. Zuvor hatte US-Präsident Donald Trump „erhebliche“…

Swiss drugmaker Novartis to invest $23bn in US manufacturing and R&D

Pharma group builds out American supply chains as part of preparations for potential US tariffs…

Novartis kündigt Milliarden-Investitionen in den USA an

BASEL/EAST HANOVER US (dpa-AFX) - Der Pharmakonzern Novartis will in den USA in den nächsten fünf…

Novartis follows Lilly and J&J in announcing multibillion-dollar US manufacturing investment

With US tariffs on pharmaceuticals likely to come very soon, another of the worlds largest drugmakers is announcing plans to…

Novartis plans to invest $23 billion in U.S. plants as Trump renews drug tariff threats

Swiss drugmaker Novartis said it plans to spend $23 billion to build and expand 10 facilities in the U.S. as…

Following pledges from Lilly and J&J, Novartis unveils $23B US investment to beef up manufacturing, R&D

On the heels of similar investment pledges by Eli Lilly and Johnson & Johnson, Switzerland’s Novartis is stepping up to…

Novartis-Aktie: Novartis will 23 Milliarden Dollar in Expansion in den USA investieren

Dazu sollen die Forschungs- und Entwicklungsaktivitäten mit einem neuen, 1,1 Milliarden Dollar teuren Forschungszentrum im Raum San Diego verstärkt werden,…

Novartis Pledges $23 Billion US Investment as Tariffs Loom

Swiss pharmaceutical giant Novartis AG said it would invest $23 billion in the US over the next five years to…

Novartis invests $23 billion in US manufacturing By Investing.com

Novartis invests $23 billion in US manufacturing…

Novartis plans to invest $23 billion in US plants as Trump renews drug tariff threats

Swiss drugmaker Novartis said on Thursday it plans to spend $23 billion to build and expand 10 facilities in the…

Novartis Plans $23B Investment in US Facilities as Trump Threatens Pharma Tariffs

Swiss pharmaceutical giant Novartis said it plans to invest $23 billion in the construction and expansion of U.S. facilities, as…

Zölle in Kraft – Börsen weiter auf Achterbahnfahrt

Auch Öl gerät unter Preisdruck. Der Dax gibt rund 4 Prozent ab, manche asiatische Börse und mancher Schweizer Pharmawert noch…

Novartis Buy

FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Novartis mit einem Kursziel von 115 Franken auf…

Deutsche Bank Research lässt Novartis auf Buy, Ziel 115 Franken

FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Novartis mit einem Kursziel von 115 Franken auf…

JPMORGAN stuft NOVARTIS AG auf Neutral

NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat Novartis auf "Neutral" mit einem Kursziel von 95 Franken belassen. Analyst…

Novartis After Sandoz: The Business Without Generics

…

Novartis Buy

FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat Novartis auf "Buy" mit einem Kursziel von 115 Franken belassen. Nach einer…

Deutsche Bank Research lässt Novartis auf Buy; Ziel 115 Franken

FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat Novartis auf "Buy" mit einem Kursziel von 115 Franken belassen. Nach einer…

Deutsche Bank hebt Ziel für Novartis auf 115 Franken - Buy

FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Novartis nach einer Telefonkonferenz mit Prostatakrebs-Experten von 110 auf…

Bernstein belässt Novartis auf Outperform - Ziel 115 Franken

NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat die Einstufung für Novartis auf "Outperform" mit einem Kursziel von…

Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)

Ad hoc announcement pursuant to Art. 53 LR…

FDA Grants Accelerated Approval to NVS Kidney Disease Drug

Novartis strengthens its renal disease portfolio with accelerated approval of another drug for immunoglobulin A nephropathy.…

Novartis (NVS) Could Be a Great Choice

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy…

Hauck Aufhäuser IB lässt Eckert & Ziegler auf Buy, Ziel 66 Euro

HAMBURG (dpa-AFX Analyser) - Hauck Aufhäuser Investment Banking hat die Einstufung für Eckert & Ziegler auf "Buy" mit einem…

Novartis: Enorm wichtiger Meilenstein – Marktpotenzial fast verdreifacht

Der Pharma-Riese Novartis konnte am vergangenen Freitag eine enorm wichtige Zulassung verbuchen. Das radiopharmazeutische Medikament Pluvicto darf in den USA…

Novartis: Enorm wichtiger Meilenstein – Marktpotenzial fast verdreifacht

Der Pharma-Riese Novartis konnte am vergangenen Freitag eine enorm wichtige Zulassung verbuchen. Das radiopharmazeutische Medikament Pluvicto darf in den USA…

Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of Novartis

Basel, March 31, 2025 – Novartis announced today the appointment of Karen Hale to the expanded role of Chief Legal…

5 Large Drug Stocks to Watch as Industry Recovers

R&D innovation is likely to remain a major focus area in 2025. In the Large-Cap Pharmaceuticals industry, AbbVie (ABBV), Novo…

FDA Approves Novartis Drug for Rare Kidney Disease Treatment

Novartis wins FDA approval for the label expansion of Fabhalta for a third indication - treatment of adults with C3…

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)…

dpa-AFX ProFeed